Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Myricx Bio has raised $115.3M in total funding. The most recent round was Series A. The last funding was announced in July 2024.
Myricx Bio's investors include Eli Lilly, Brandon Capital, Novo Holdings, Sofinnova Partners, Abingworth.
Myricx Bio is headquartered in London, United Kingdom.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Myricx Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Myricx Bio — Funding & Investors." VCBacked, July 8, 2024, https://www.vcbacked.co/company/myricx-bio. Accessed October 26, 2026.
VCBacked. (2024). Myricx Bio — Funding & Investors. Retrieved October 26, 2026, from https://www.vcbacked.co/company/myricx-bio
{{cite web |title=Myricx Bio — Funding & Investors |url=https://www.vcbacked.co/company/myricx-bio |website=VCBacked |access-date=October 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated